AUPH News and Press, Aurinia Pharmaceuticals Inc From 06/06/22

At 2022 Russell indexes annual reconstitution, following notable health care stocks will be added to and deleted from the Russell 3000 Index. Notable additions: Clover Health Investments (CLOV), Aurinia Pharmaceuticals (AUPH), Nano-X Imaging (NNOX), ADMA Biologics (ADMA),&...

-The post-hoc analysis based on the updated treatment recommendations was presented at the EULAR 2022 European Congress of Rheumatology Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that ...

Aurinia Pharmaceuticals won approval for Lupkynis - to treat Lupus Nephritis - in January 2021. The therapy was considered to have blockbuster (>$1bn per annum) sales potential, but earned only $21.6m in Q1'22. Aurinia management blamed Omicron but will need to show improvement...

Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis (voclosporin) will be approved for lupus nephritis in the European territories. About $21.6 million in net revenue was generated for Q1 of 2022, due to sales of Lupkynis; if ...

Aurinia Pharmaceuticals (NASDAQ:AUPH) said that data from a study showed that its lupus nephritis treatment Lupkynis (voclosporin) led to preservation of kidney function over three years of treatment. The AURORA 2 study is a continuation study of patients after one year of treatment for anoth...

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the ...

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2022 Earnings Conference Call May 10, 2022, 08:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Max Cola...

The commercial-stage biotech, Aurinia Pharmaceuticals (NASDAQ:AUPH) is trading lower in the pre-market Tuesday despite reporting better than expected revenue for 1Q 2022 as the company pointed to COVID impact on sales for its lupus nephritis therapy, Lupkynis (voclosporin). Following its FDA ...

Aurinia Pharma press release (NASDAQ:AUPH): Q1 GAAP EPS of -$0.27 in-line. Revenue of $21.63M (+2276.9% Y/Y) beats by $2.39M. The company maintains net revenue guidance range of $115M-$135M from sales of LUPKYNIS for 2022 vs. consensus of $138.01M. For further details see: Aurinia Pharm...